Rise of defibrillation energy requirement under carvedilol therapy.
Carvedilol, a nonselective beta 1-, beta 2-adrenoreceptor blocking agent with alpha 1-adrenoreceptor blocking activity, is often prescribed as an adjunctive pharmacological therapy in patients who received an ICD. Despite the new ICD technology, concomitant antiarrhythmic therapy still represents the most important concern in patients with an ICD. As illustrated by this case, carvedilol may also increase the energy requirement for internal defibrillation.
Melichercik
J
J
Department of Cardiology, Heart Center Lahr/Baden, Lahr, Germany. jur.mel@heart-lahr.com
Goepfrich
M
M
Breidenbach
T
T
Von Hodenberg
E
E
D000368:Aged; D002227:Carbazoles / Q000008:administration & dosage / Q000009:adverse effects*; D000077261:Carvedilol; D003131:Combined Modality Therapy; D017147:Defibrillators, Implantable; D025802:Electric Capacitance; D006801:Humans; D008297:Male; D011412:Propanolamines / Q000008:administration & dosage / Q000009:adverse effects*; D017180:Tachycardia, Ventricular / Q000209:etiology / Q000628:therapy*
D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol